Business Context and Reporting Period
This Form 8-K Current Report is filed by Neuronetics, Inc. (Nasdaq: STIM) on July 9, 2026. The filing discloses significant changes in executive leadership, specifically the departure of the Chief Legal Officer and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data contained within this report is limited to executive compensation and severance arrangements.
- Separation Payment (W. Andrew Macan): $475,087.50 (paid over 12 months).
- Retention Bonus (W. Andrew Macan): $231,750.00.
- Retention Award (W. Andrew Macan): 164,361 Restricted Stock Units (vesting on separation date).
- New CFO Base Salary (Nir Naor): $480,000 annually.
- New CFO Target Bonus (Nir Naor): 50% of base salary.
- New CFO Equity Grant (Nir Naor): 500,000 Restricted Stock Units (vesting over 4 years).
Material Changes Versus Prior Period
The primary material change reported is a shift in senior management personnel:
- Departure: W. Andrew Macan, Executive Vice President, Chief Legal Officer, and Corporate Secretary, is departing with a separation date of August 15, 2026. The filing states this departure is not the result of any dispute with the Company.
- Appointment: Nir Naor has been appointed as Executive Vice President, Chief Financial Officer, and Treasurer, effective July 23, 2026.
- Internal Promotion: Cory Anderson was promoted to Executive Vice President, General Manager of Greenbrook.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, revenue outlook, or management commentary regarding future business performance. The focus is strictly on the terms of the executive transition.
Risks and Contingencies: The filing notes that the new CFO, Nir Naor, brings over 20 years of experience in finance and life sciences, including a track record of achieving profitability and cash flow positivity at a prior company (Axogen, Inc.). No specific risks or contingencies related to the company's operations are disclosed in this report.
Important Facts for Investor Verification
- Verify the total cost of the executive transition, including the $475,087.50 severance, $231,750 retention bonus, and the value of the 164,361 RSUs granted to the departing executive.
- Review the full text of the Separation Agreement (Exhibit 10.2) and Offer Letter (Exhibit 10.1) for additional covenants or conditions not summarized in the 8-K.
- Confirm the start date of the new CFO, Nir Naor, is July 23, 2026, and monitor for any interim financial reporting gaps during the transition.
- Check subsequent filings for the impact of the new CFO's strategic direction, given his background in turning around life sciences companies.